TY - JOUR
T1 - Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
AU - Takamori, Shinkichi
AU - Takada, Kazuki
AU - Shimokawa, Mototsugu
AU - Matsubara, Taichi
AU - Fujishita, Takatoshi
AU - Ito, Kensaku
AU - Toyozawa, Ryo
AU - Yamaguchi, Masafumi
AU - Okamoto, Tatsuro
AU - Yoneshima, Yasuto
AU - Tanaka, Kentaro
AU - Okamoto, Isamu
AU - Tagawa, Tetsuzo
AU - Mori, Masaki
N1 - Funding Information:
As a potential personal and financial conflict of interest, Mototsugu Shimokawa reports personal fees from Sysmex. Ryo Toyozawa reports personal fees from Kyowa Hakko Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., and grants from Abbvie, Daiichi Sankyo Co. Ltd., Pfizer Japan, Takeda Pharmaceutical Co. Ltd. Masafumi Yamaguchi reports personal fees from AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd, Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co., Ltd., and grants from Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc. Kentaro Tanaka reports personal fees from Astrazeneca, Chugai, Eli Lilly, Bristol Myers Squibb, Ono, Boehlinger Ingelheim, Abbvie, Novartis, Pfizer, KyowaKirin, MSD, and Taiho; grants from Chugai, Ono, and Boehringer Ingelheim. Isamu Okamoto reports grants and personal fees from AstraZeneca, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD Oncology, grants and personal fees from Lilly, grants from Astellas Pharma, grants and personal fees from Bristol-Myers Squibb, grants from Novartis, grants and personal fees from Chugai Pharma, personal fees from Pfizer, grants from AbbVie. Tetsuzo Tagawa reports grants from Chugai Pharmaceutical Co., Ltd., Roche Diagnostics. Masaki Mori reports grants from Chugai Pharmaceutical Co., Ltd. The other authors declare no conflicts of interest. All the authors declare no conflicts of interest in association with this study.
Funding Information:
We thank Edanz Group ( https://en-author-services.edanzgroup.com/ac ) for editing a draft of this manuscript. The publication fee was funded by Japanese Foundation for Multidisciplinary Treatment of Cancer.
PY - 2021/2
Y1 - 2021/2
N2 - Objectives: Immune checkpoint inhibitors (ICIs) have become one of the standard therapies in non-small-cell lung cancer (NSCLC). Although inflammatory indices, including Glasgow prognostic score (GPS), modified Glasgow prognostic score (mGPS), and C-reactive protein/albumin ratio (CAR) were reported to be reliable predictors for survival in cancer patients, their clinical utility in NSCLC patients treated with ICIs is unknown. Materials and methods: Advanced or recurrent NSCLC patients (n = 304) treated with ICI monotherapy at the National Hospital Organization Kyushu Cancer Center and Kyushu University Hospital between January 2016 and December 2019 were analyzed. Information on patient demographics, GPS, mGPS, and CAR at diagnosis were collected. The time-dependent area under curves (AUCs) of receiver operating characteristic curves for the prediction of overall survival (OS) for each factor were compared. Results: Of the three indices, GPS was the most significantly correlated with the degree of disease control rate (DCR) (DCR of GPS of 0, 1, and 2: 63.6 %, 49.4 %, and 41.4 %, respectively). The time-dependent AUC values of GPS for the prediction of OS were superior to those of mGPS and CAR (time-dependent AUC values of GPS, mGPS, and CAR for the prediction of 1-year OS: 0.7005, 0.6736, and 0.6565, respectively). GPS was significantly correlated with performance status (PS) (P < 0.0001) and clinical stage (P = 0.0139). GPS in combination with PS effectively predicted survival at 1 year ranging from 83.5 % (GPS = 0, PS = 0) to 25.0 % (GPS = 2, PS = 2, 3). A multivariable analysis revealed that GPS was an independent predictor of PFS and OS (P = 0.0009 and P = 0.0100, respectively). Conclusions: We report for the first time that GPS represents a simple and useful prognostic factor in NSCLC patients treated with ICIs and should be validated prospectively.
AB - Objectives: Immune checkpoint inhibitors (ICIs) have become one of the standard therapies in non-small-cell lung cancer (NSCLC). Although inflammatory indices, including Glasgow prognostic score (GPS), modified Glasgow prognostic score (mGPS), and C-reactive protein/albumin ratio (CAR) were reported to be reliable predictors for survival in cancer patients, their clinical utility in NSCLC patients treated with ICIs is unknown. Materials and methods: Advanced or recurrent NSCLC patients (n = 304) treated with ICI monotherapy at the National Hospital Organization Kyushu Cancer Center and Kyushu University Hospital between January 2016 and December 2019 were analyzed. Information on patient demographics, GPS, mGPS, and CAR at diagnosis were collected. The time-dependent area under curves (AUCs) of receiver operating characteristic curves for the prediction of overall survival (OS) for each factor were compared. Results: Of the three indices, GPS was the most significantly correlated with the degree of disease control rate (DCR) (DCR of GPS of 0, 1, and 2: 63.6 %, 49.4 %, and 41.4 %, respectively). The time-dependent AUC values of GPS for the prediction of OS were superior to those of mGPS and CAR (time-dependent AUC values of GPS, mGPS, and CAR for the prediction of 1-year OS: 0.7005, 0.6736, and 0.6565, respectively). GPS was significantly correlated with performance status (PS) (P < 0.0001) and clinical stage (P = 0.0139). GPS in combination with PS effectively predicted survival at 1 year ranging from 83.5 % (GPS = 0, PS = 0) to 25.0 % (GPS = 2, PS = 2, 3). A multivariable analysis revealed that GPS was an independent predictor of PFS and OS (P = 0.0009 and P = 0.0100, respectively). Conclusions: We report for the first time that GPS represents a simple and useful prognostic factor in NSCLC patients treated with ICIs and should be validated prospectively.
UR - http://www.scopus.com/inward/record.url?scp=85097732988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097732988&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2020.11.026
DO - 10.1016/j.lungcan.2020.11.026
M3 - Article
AN - SCOPUS:85097732988
VL - 152
SP - 27
EP - 33
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
ER -